Japan’s Takeda engaged in antitrust scheme to delay generic constipation drug, US jury finds

Breaking News A US jury has found Japanese pharmaceutical company Takeda guilty of engaging in an antitrust scheme to delay the entry of a generic constipation drug into the market. The verdict stems from allegations that Takeda attempted to stifle competition by manipulating the patent process. The company now faces potential fines and penalties for its actions.